A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...

therapy for dry age-related macular degeneration (AMD), today announced clinical data from its Phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE ...

Retinitis pigmentosa (RP) is a rare inherited condition that causes the gradual death of photoreceptors (light-sensing cells) ...

Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This ...

With promising results in animal models, researchers are now planning clinical trials to evaluate the safety and ...

The "Dry AMD -Epidemiology - 2034" report delivers an in-depth understanding of dry AMD, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain ...

Avirmax Biopharma Inc. has begun IND-enabling studies of ABI-201, a gene therapy for dry age-related macular degeneration (AMD). ABI-201 is an AAV vector that delivers three genes to correct the ...

a separate analysis of these CSF samples to identify pathways associated with dry AMD that were altered by treatment with zervimesine; c) an in vitro study conducted in collaboration with ...

“Retinal pigment epithelial (RPE ... has the potential to alter the biological processes that contribute to dry AMD. However, at this time, the Company intends to focus its current financial ...

"Retinal pigment epithelial (RPE ... has the potential to alter the biological processes that contribute to dry AMD. However, at this time, the Company intends to focus its current financial ...